肾康注射液治疗糖尿病肾病临床效果分析

Curative Analysis on Shenkang Injection in the Treatment of Diabetic Nephropathy

目的:评价肾康注射液治疗糖尿病肾病的临床效果。方法:100例糖尿病肾病患者随机分为两组,各50例。对照组常规治疗,治疗组在此基础上加用肾康注射液。对比两组患者治疗前后各项生化指标变、血压变化以及不良反应发生情况。结果:治疗后,两组患者血糖、血清肌酐、总胆固醇均有明显改善,组间相比并无显著性差异(P>0.05);治疗后,治疗组24h尿蛋白定量较治疗前有显著降低,效果显著优于对照组(P<0.05);两组血压均有不同程度降低(P<0.05),其中治疗组收缩压、舒张压水平均较对照组低,但差异不具有统计学意义(P>0.05);两组不良反应发生率分别为6.0%、4.0%,相比无显著差异(P>0.05)。结论:肾康注射液能够降低糖尿病肾病患者尿蛋白水平,安全可靠,值得临床推广。

Objective： To evaluate the clinical effect of renal injection for treatment of diabetic nephropathy. Methods： 100cases of diabetic nephropathy patients were randomly divided into two groups, 50cases each. The controlled group was given conventional treatment, the treatment group on the basis of combined with Shengkang Injection, and compared two groups＇ biochemical indexes, blood pressure change, and adverse reactions occur before and after treatment. Results ： After treatment, two groups of patients with blood glucose, serum creatinine, total cholesterol were significantly improved, compared between groups was. no significant difference （P〉0. 05 ） ; 24hours urine protein after treatment, the treatment group had significantly lower than before treatment, and quantitative effect was significantly better than the controlled group （P〈0. 05 ） ; two groups all had drop of blood pressure （ P〈0. 05）, the systolic pressure, diastolic blood pressure levels of the treatment group were lower than the controlled group, but no statistically significant difference （ P 〉 0. 05 ）. Incidence of adverse reactions to the two groups were 6.0%, 4.0%, there showed no significant difference （ P 〉 0. 05）. Conclusion ： Shengkang Injection can reduce urine protein lewds of diabetic nephropathy patients, safe and reliable, worthy of clinical promotion.